

Stefano Lancellotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6267212/publications.pdf>

Version: 2024-02-01

44
papers

1,469
citations

361045

20
h-index

315357

38
g-index

44
all docs

44
docs citations

44
times ranked

2106
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct oral anticoagulants and therapeutic adherence: do not let your guard down. <i>Acta Cardiologica</i> , 2022, 77, 243-249.	0.3	3
2	The Von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis. , 2022, 1, .		0
3	ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study. <i>Digestive and Liver Disease</i> , 2022, 54, 1672-1680.	0.4	11
4	Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a caseâ€“control study. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 285-289.	0.5	16
5	Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated With Combined Therapy. <i>Frontiers in Pediatrics</i> , 2021, 9, 743206.	0.9	7
6	Noncanonical type 2B von Willebrand disease associated with mutations in the VWF Dâ€“2D3 and D4 domains. <i>Blood Advances</i> , 2020, 4, 3405-3415.	2.5	6
7	Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 413-421.	1.0	9
8	Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. <i>TH Open</i> , 2019, 03, e123-e131.	0.7	4
9	Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. <i>ESC Heart Failure</i> , 2019, 6, 884-888.	1.4	5
10	Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 528-531.	1.0	21
11	Mechanochemistry of von Willebrand factor. <i>Biomolecular Concepts</i> , 2019, 10, 194-208.	1.0	32
12	Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests. <i>Blood</i> , 2019, 134, 1178-1178.	0.6	0
13	Apixaban Interacts with Haemoglobin: Effects on Its Plasma Levels. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1701-1712.	1.8	4
14	The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. <i>Thrombosis and Haemostasis</i> , 2016, 115, 51-62.	1.8	14
15	Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. <i>Internal and Emergency Medicine</i> , 2016, 11, 959-967.	1.0	40
16	Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1226-1237.	1.9	48
17	Increased production of gliotoxin is related to the formation of biofilm by <i>Aspergillus fumigatus</i> : an immunological approach. <i>Pathogens and Disease</i> , 2014, 70, 379-389.	0.8	7
18	Congenital Prothrombin Deficiency: An Update. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 596-606.	1.5	68

#	ARTICLE	IF	CITATIONS
19	The type 2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1688-1698.	1.9	15
20	PROTEOLYTIC PROCESSING OF VON WILLEBRAND FACTOR BY ADAMTS13 AND LEUKOCYTE PROTEASES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013058.	0.5	15
21	The Oxidative Modification of Von Willebrand Factor Is Associated with Thrombotic Angiopathies in Diabetes Mellitus. <i>PLoS ONE</i> , 2013, 8, e55396.	1.1	30
22	Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. <i>Biochemical Journal</i> , 2012, 442, 423-432.	1.7	18
23	Modeling ADAMTS13-von Willebrand Factor interaction: Implications for oxidative stress-related cardiovascular diseases and type 2A von Willebrand Disease. <i>Biophysical Chemistry</i> , 2012, 160, 1-11.	1.5	7
24	Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. <i>Clinical Science</i> , 2011, 121, 555-564.	1.8	32
25	Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTS13. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1620-1627.	1.9	17
26	Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1744-1751.	1.9	22
27	Structure and Proteolytic Properties of ADAMTS13, A Metalloprotease Involved in the Pathogenesis of Thrombotic Microangiopathies. <i>Progress in Molecular Biology and Translational Science</i> , 2011, 99, 105-144.	0.9	12
28	Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors. <i>Current Medicinal Chemistry</i> , 2011, 18, 2205-2214.	1.2	17
29	Prostaglandin E2 Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 391-402.	1.3	45
30	Haemostatic system in inflammatory bowel diseases: New players in gut inflammation. <i>World Journal of Gastroenterology</i> , 2011, 17, 594.	1.4	50
31	The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation. <i>Blood</i> , 2010, 116, 5371-5376.	0.6	23
32	Ristocetin-induced self-aggregation of von Willebrand factor. <i>European Biophysics Journal</i> , 2010, 39, 1597-1603.	1.2	30
33	Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. <i>Free Radical Biology and Medicine</i> , 2010, 48, 446-456.	1.3	56
34	Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 416-418.	1.9	0
35	Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. <i>FASEB Journal</i> , 2010, 24, 3970-3980.	0.2	75
36	High-Mobility Group Box-1 Protein Promotes Angiogenesis After Peripheral Ischemia in Diabetic Mice Through a VEGF-Dependent Mechanism. <i>Diabetes</i> , 2010, 59, 1496-1505.	0.3	110

#	ARTICLE	IF	CITATIONS
37	Congenital Prothrombin Deficiency. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 367-381.	1.5	53
38	Effects of rehabilitation treatment on thyroid function. <i>Clinical Endocrinology</i> , 2009, 70, 644-649.	1.2	4
39	Kinetic study of von Willebrand factor self-aggregation induced by ristocetin. <i>Biophysical Chemistry</i> , 2009, 144, 101-107.	1.5	17
40	Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. <i>Journal of Hepatology</i> , 2009, 51, 682-689.	1.8	409
41	Nucleotide-Derived Thrombin Inhibitors: A New Tool for an Old Issue. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2009, 7, 19-28.	0.4	23
42	Mechanistic Studies on ADAMTS13 Catalysis. <i>Biophysical Journal</i> , 2008, 95, 2450-2461.	0.2	22
43	Effects of rehabilitation on quality of life in patients with chronic stroke. <i>Brain Injury</i> , 2008, 22, 451-456.	0.6	38
44	Fibrinogen-elongated \hat{I}^3 Chain Inhibits Thrombin-induced Platelet Response, Hindering the Interaction with Different Receptors. <i>Journal of Biological Chemistry</i> , 2008, 283, 30193-30204.	1.6	34